Stan Heptinstall

COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS

Robert Altman, L Carreras, Rubén Sierra Díaz et al. · Oxford University Research Archive (ORA) (University of Oxford) · 1994 · 3.3K citations

Thrombosis, Ischemic Stroke, Cardiovascular Disease +9

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

Steen Husted, Håkan Emanuelsson, Stan Heptinstall et al. · European Heart Journal · 2006 · 738 citations · Full text

The central role of the P_<i>2T</i> receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity

Robert F. Storey, H. M. Sanderson, Ann E. White et al. · British Journal of Haematology · 2000 · 290 citations

DIFFERENTIAL INHIBITION BY LOW-DOSE ASPIRIN OF HUMAN VENOUS PROSTACYCLIN SYNTHESIS AND PLATELET THROMBOXANE SYNTHESIS

S P Hanley, S R Cockbill, J A Bevan et al. · The Lancet · 1981 · 197 citations

Thrombopoiesis, Thrombosis, Venous Thrombosis +9

Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial

Philip M. Bath, Lisa J Woodhouse, Jason P. Appleton et al. · The Lancet · 2017 · 176 citations · Full text